Kura Oncology, Inc.
Status: Publicly traded
Direct answer
Kura Oncology, Inc. is publicly traded on NASDAQ under the ticker KURA.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid...
Can you invest in Kura Oncology, Inc.?
Yes. Kura Oncology, Inc. trades publicly on NASDAQ as KURA.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Kura Oncology, Inc.
Detailed equity research is provided by MarketSnap.